Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
OBJECTIVE
To assess the effects of androgen deprivation therapy on body composition in men with nonmetastatic prostate cancer.


METHODS
In a multicenter study, men with Stage M0 prostate cancer were prospectively evaluated during initial androgen deprivation therapy (gonadotropin-releasing hormone agonist or bilateral orchiectomy). The main outcomes were changes in weight, percentage fat mass, and percentage lean mass from baseline to 12 months.


RESULTS
Seventy-nine subjects were assessed. Serum testosterone concentrations decreased by 79.7% +/- 3.0% (P <0.001). Weight increased by 1.8% +/- 0.5% (P <0.001). The percentage fat mass increased by 11.0% +/- 1.7%, and the percentage lean mass decreased by 3.8% +/- 0.6% (P <0.001 for each comparison).


CONCLUSIONS
Androgen deprivation therapy increased weight and fat mass and decreased lean mass in men with nonmetastatic prostate cancer.
Smith
Matthew R
MR
Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
D000273:Adipose Tissue / Q000187:drug effects; D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects / Q000502:physiology*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects / Q000502:physiology*; D005485:Flutamide / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D013739:Testosterone / Q000037:antagonists & inhibitors / Q000097:blood
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D005485:Flutamide